The effect of sodium‐glucose cotransporter‐2 inhibitors on inflammatory biomarkers: A meta‐analysis of randomized controlled trials
Authors' conclusion
Our analysis shows that SGLT2 inhibitors likely improve adipokine biomarkers and insulin sensitivity, but there is little evidence that SGLT2 inhibitors improve other inflammatory biomarkers including CRP.
Study context
- Population
- Randomized controlled trials (RCTs) of SGLT2 inhibitors reporting inflammatory biomarkers, adipokine profiles and insulin sensitivity; participants 63.3% male, mean age 62 ± 8.6 years
- Participants
- 14,967 participants38 RCTs
- Comparison
- SGLT2 inhibitors vs placebo or control
- Outcome
- Inflammatory biomarkers
- Follow-up
- Median (IQR) 16 (12-24) weeks
Pooled result
As reported in the abstract
Inflammatory biomarkers and adipokines
SGLT2 inhibitors vs Placebo/controlSMD (95% CI)
Adiponectin,vs placebo
0.34(0.23–0.45)
Tumour necrosis factor receptor-1,vs placebo
−0.13(−0.20 to −0.06)
Leptin,vs control
−0.20(−0.33 to −0.07)
SGLT2 inhibitors vs Placebo/controlMD, pg/mL (95% CI)
Interleukin-6,vs placebo
−0.85(−1.32 to −0.38)
Further pooled results
| Outcome | MD (95% CI) | |
|---|---|---|
| HOMA-IRvs control | −0.83 (−1.32 to −0.33) | |
| −2−101Difference (linear scale) |
Original publication
The effect of sodium‐glucose cotransporter‐2 inhibitors on inflammatory biomarkers: A meta‐analysis of randomized controlled trials. Diabetes Obes Metab. Published 11 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →